Only 60 percent of treatments for rare disorders make it into Canada. For most of these drugs, it will take another six years for it to be approved after United States and Europe have it available. In an effort to change the rare disease landscape in Canada, the Canadian Organization for Rare Disorders (CORD) has released a multi-pronged rare disease strategy for the country. We spoke to Durhane Wong-Rieger, President and CEO of the Canadian Organization for Rare Disorders, about the need for a national strategy, the effort to pass a regulatory framework for orphan drugs, and what it will take to make a national strategy a reality.